JAMA Neurol:疫苗接种不会增加神经脱髓鞘疾病患病风险

2014-10-29 kimfrost 丁香园

疫苗接种在临床实践中的应用相当广泛,因此对与疫苗相关的风险,哪怕再微小都是值得注意的。近期有假说担忧,疫苗能小幅增加多发性硬化(MS)和其它获得性中枢神经系统脱髓鞘性症状(ADS)的风险,但是关于此说法尚有争议。 大部分研究关注的焦点是乙肝疫苗导致的MS风险,因为乙肝疫苗有髓磷脂基础蛋白(myelin basic protein)分子拟态的潜在可能性,而这一蛋白在动物模型中是MS的关键免

疫苗接种在临床实践中的应用相当广泛,因此对与疫苗相关的风险,哪怕再微小都是值得注意的。近期有假说担忧,疫苗能小幅增加多发性硬化(MS)和其它获得性中枢神经系统脱髓鞘性症状(ADS)的风险,但是关于此说法尚有争议。

大部分研究关注的焦点是乙肝疫苗导致的MS风险,因为乙肝疫苗有髓磷脂基础蛋白(myelin basic protein)分子拟态的潜在可能性,而这一蛋白在动物模型中是MS的关键免疫优势表位。多数相关研究显示乙肝疫苗无导致MS的作用,但是有研究显示在注射乙肝疫苗后,可小幅增加成年起病MS的风险;另一研究也认为儿童在注射乙肝疫苗3年或更久以后可出现MS。

另有一些病例报道称,年轻女性在注射人乳头瘤病毒(HPV)疫苗2至4周后突然出现中枢神经系统ADS;部分病例在注射疫苗当时就出现症状。这提示HPV疫苗可能促进相关疾病从亚临床状态向临床状态转化。

为明确注射疫苗,尤其是注射乙肝疫苗和HPV疫苗是否会增加MS和其它中枢神经系统ADS的风险,美国凯撒医疗集团的一个研究组进行了一项巢式病例对照研究。该研究结果发表在近期出版的JAMA Neurology杂志上。

该研究从南加州凯撒医疗集团获得的完整电子健康记录资料数据库中筛选出2008-2011年间,有中枢神经系统ADS的780名患者,每一名患者设立5个同年龄、性别和居住地的对照(共3885名)。通过上述数据库可获得受试者接种疫苗的情况(特别是乙肝疫苗和HPV疫苗)。然后通过条件逻辑回归分析所有ADS类型的情况,修正因素包括种族、卫生服务使用情况、共患病和前驱感染疾病等。

纳入研究的92名患者和459名对照为9-26岁的女性,处于接受HPV疫苗注射的年龄范围。研究结果显示,注射乙肝疫苗、HPV疫苗、或其它任何疫苗均与最长3年以后出现中枢神经系统ADS的风险无相关性。任意一种疫苗接种在较年轻(<50岁)人群中,可增加接种30天内出现中枢神经系统ADS的风险(OR 2.32,95%CI 1.18-4.57)。

研究结论认为,在疫苗接种和MS或其它中枢神经系统ADS之间不存在长期相关性。接种疫苗短期内增加患病风险,提示疫苗可能促进了已患病患者的疾病状态从亚临床变为活动性的过程。该研究结果支持继续现有的疫苗接种政策。

原始出处:

Langer-Gould A1, Qian L2, Tartof SY2, Brara SM3, Jacobsen SJ2, Beaber BE3, Sy LS2, Chao C2, Hechter R2, Tseng HF2.Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.JAMA Neurol. 2014 Oct 20. doi: 10.1001/jamaneurol.2014.2633. [Epub ahead of print]


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999454, encodeId=d59719994549e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 00:31:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755052, encodeId=f8431e55052dc, content=<a href='/topic/show?id=d1011021391e' target=_blank style='color:#2F92EE;'>#髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102139, encryptionId=d1011021391e, topicName=髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28436833652, createdName=xiaogang329, createdTime=Wed Apr 08 19:31:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257815, encodeId=beb5125e81546, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281718, encodeId=d4c31281e180c, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516396, encodeId=7f8a151639647, content=<a href='/topic/show?id=8160852e55c' target=_blank style='color:#2F92EE;'>#脱髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85275, encryptionId=8160852e55c, topicName=脱髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]
    2015-09-19 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999454, encodeId=d59719994549e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 00:31:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755052, encodeId=f8431e55052dc, content=<a href='/topic/show?id=d1011021391e' target=_blank style='color:#2F92EE;'>#髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102139, encryptionId=d1011021391e, topicName=髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28436833652, createdName=xiaogang329, createdTime=Wed Apr 08 19:31:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257815, encodeId=beb5125e81546, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281718, encodeId=d4c31281e180c, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516396, encodeId=7f8a151639647, content=<a href='/topic/show?id=8160852e55c' target=_blank style='color:#2F92EE;'>#脱髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85275, encryptionId=8160852e55c, topicName=脱髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999454, encodeId=d59719994549e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 00:31:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755052, encodeId=f8431e55052dc, content=<a href='/topic/show?id=d1011021391e' target=_blank style='color:#2F92EE;'>#髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102139, encryptionId=d1011021391e, topicName=髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28436833652, createdName=xiaogang329, createdTime=Wed Apr 08 19:31:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257815, encodeId=beb5125e81546, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281718, encodeId=d4c31281e180c, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516396, encodeId=7f8a151639647, content=<a href='/topic/show?id=8160852e55c' target=_blank style='color:#2F92EE;'>#脱髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85275, encryptionId=8160852e55c, topicName=脱髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999454, encodeId=d59719994549e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 00:31:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755052, encodeId=f8431e55052dc, content=<a href='/topic/show?id=d1011021391e' target=_blank style='color:#2F92EE;'>#髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102139, encryptionId=d1011021391e, topicName=髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28436833652, createdName=xiaogang329, createdTime=Wed Apr 08 19:31:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257815, encodeId=beb5125e81546, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281718, encodeId=d4c31281e180c, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516396, encodeId=7f8a151639647, content=<a href='/topic/show?id=8160852e55c' target=_blank style='color:#2F92EE;'>#脱髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85275, encryptionId=8160852e55c, topicName=脱髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1999454, encodeId=d59719994549e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 00:31:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755052, encodeId=f8431e55052dc, content=<a href='/topic/show?id=d1011021391e' target=_blank style='color:#2F92EE;'>#髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102139, encryptionId=d1011021391e, topicName=髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28436833652, createdName=xiaogang329, createdTime=Wed Apr 08 19:31:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257815, encodeId=beb5125e81546, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281718, encodeId=d4c31281e180c, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516396, encodeId=7f8a151639647, content=<a href='/topic/show?id=8160852e55c' target=_blank style='color:#2F92EE;'>#脱髓鞘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85275, encryptionId=8160852e55c, topicName=脱髓鞘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Oct 31 00:31:00 CST 2014, time=2014-10-31, status=1, ipAttribution=)]

相关资讯

Nat Rev Neurol:那他珠单抗-芬戈莫德多发性硬化转换疗法的评估

近日Nature杂志子刊Nat. Rev. Neurol 新闻与观点一栏,就法国尼斯大学Cohen 博士等学者于2014年4月发表在JAMA Neurol 杂志上的多发性硬化(MS)转换疗法——那他珠单抗转换为芬戈莫德治疗一文,进行了评价与讨论。具体内容如下:那他珠单抗被批准用于多发性硬化症的治疗,开启了高效免疫调节新时代。遗憾的是,并非所有患者对那他珠单抗治疗均反应良好,并且它的益处也被进展性多

Neurology:多发性硬化患者ICU入院率高

近期,加拿大曼尼托巴大学内科系的Ruth Ann Marrie教授等在Neurology杂志发表了关于多发性硬化(MS)患者重症监护室(ICU)入院率及死亡率的调查结果,该调查的目的在于探索MS患者和一般人群ICU使用情况以及预后的差异。 该研究筛查了1984年至2010年间加拿大曼尼托巴省患者的临床数据资料,最终一共入组了5035例MS患者,并按5:1的比例入组了与之年龄、性别、以及居住地相匹

Radiology:某游戏机使多发性硬化患者少跌倒

多发性硬化(MS)是一种中枢神经系统疾病,以肌肉无力为特征,导致协调与平衡问题。一项新的研究提示,一种家用电视游戏机——任天堂Wii的平衡板附件可以帮助病人降低意外跌倒风险。 该研究近期发表于《放射学》(Radiology)杂志。研究揭示,对使用视频游戏平衡板的MS患者进行的磁共振成像(MRI)检查表明,与平衡和运动相关的大脑连接(brain connections)发生有益的改变。 原始

Neurology:MS患儿的脑后部损伤与认知功能障碍

多发性硬化(MS)是一种常见的高复发率、高致残率的神经系统疾病。高达10%的MS患者首次发作是在儿童期。与成人期起病的MS患者相比,MS患儿转化为继发进展型以及发生永久残疾的过程更加缓慢,所经时间更长。研究认为MS患儿脑灰质结构以及功能连接损害相对受限是MS患儿病程特殊的主要原因。大部分MS患儿均会出现认知功能障碍,累及记忆,注意力,执行以及语言等各方面功能。但与认知功能障碍相关的因素尚不明确。意

第一届多发性硬化及视神经脊髓炎患友会

2014年9月21日,为了普及多发性硬化及视神经脊髓炎的基本知识、介绍最新的研究进展,指导患者朋友进行恰当的治疗、康复和护理,中日友好医院神经内科专程组织了第一届多发性硬化及视神经脊髓炎患友会。 多发性硬化(multiple sclerosis,MS)和视神经脊髓炎(neuromyelitis optica,NMO)都属于中枢神经系统免疫相关性脱髓鞘性疾病。由于这两种疾病临床特点相似,都